At a glance
Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional) is a federal competitive grant from National Institutes of Health for the science & technology sector. Funding is up to $2K. Eligible applicants: Native American tribal governments (Federally recognized); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities;. Applications are accepted on a rolling basis. Apply via the official listing at www.grants.gov.
- Amount
- Up to $2K
- Deadline
- Rolling
- Type
- Competitive
- Status
- Forecasted
About this program
Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying patients at high risk of PDAC (because of genetic factors, family history and/or the presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; develop molecular- and/or imaging-based markers of pancreatic cysts and determine which lesions are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens, and data within the Consortium.The other scientific component of the PCDC will be the Management and Data Coordination Unit, which will provide support toward study design, protocol development, statistical analysis, coordination, harmonization, data management and stewardship for the trans-PCDC collaborative projects, including biorepository building effort.
Who can apply
Native American tribal governments (Federally recognized); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; City or township governments; Native American tribal organizations (other than Federally recognized tribal governments); Others (see text field entitled "Additional Information on Eligibility" for clarification); Public and State controlled institutions of higher education; County governments; Independent school districts; Small businesses; State governments; For profit organizations other than small businesses; Special district governments; Private institutions of higher education. Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
How to apply
Apply through Grants.gov using funding opportunity number PAR-26-120. Register your organization (SAM.gov + Grants.gov) before the deadline, then submit the application package listed in the official notice.
Apply at official sourceRelated grants
- NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed) NIH · See listing · May 8, 2028 Open
- NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) NIH · See listing · Sep 7, 2027 Open
- Continuation or Revision of NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UH3 Clinical Trial Required) NIH · See listing · Jan 6, 2028 Open
- The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional) NIH · See listing · Jan 7, 2028 Open